DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Actinic Keratosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2012 To 2022" report to their offering.
Actinic keratosis (AK) is portrayed by skin papules, macules or plaques coming about because of delayed presentation to hurtful UV introduction and can bring about squamous cell carcinoma. Danger of creating actinic keratosis increments with propelling age and is especially higher in men as against ladies. Around 5-20% of patients with actinic keratosis injuries create dangerous and conceivably deadly squamous cell carcinomas.
Topical treatment is a delayed treatment and nearly more compelling than different medications yet tolerant consistence is the key issue that ruins the development of this fragment. Photodynamic treatment is the quickest developing treatment all through the gauge time frame because of rising interest for non-obtrusive surgeries, and less treatment sessions are the key variables anticipated that would help this market
Asia Pacific is the quickest developing market for AK medicines. Australia has the most astounding pervasiveness of actinic keratosis going between 40% to 60% in grown-up populace. Developing mindfulness in the area and fast improvement in social insurance framework and human services use are the key development figures Asia Pacific actinic keratosis market.
- Apotex, Inc.
- Aqua Pharmaceuticals, Llc
- Dusa Pharmaceuticals, Inc. (Sun Pharma)
- Galderma S.A.
- Leo Laboratories Ltd. (Leo Pharma A/S)
- Perrigo Company Plc,
- Tolmar Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Actinic Keratosis Market, By Treatments
Chapter 5 Global Actinic Keratosis Market, By Geography
Chapter 6 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/f2zs2g/global_actinic